ERBB2 and interstitial lung disease: For instance, ILD and pneumonitis were identified as adverse events leading to the dose modification, dose delay, or treatment discontinuation of the anti-HER2 ADC trastuzumab deruxtecan in the phase 2 DESTINY-Breast01 clinical trial [65].